



Annual Report & Financial
Statements 2001



African Medical and Research Foundation

Board of Directors, Management and Administration	<i>page 1</i>
Directors' report	<i>pages 2 - 3</i>
Statement of directors' responsibilities	<i>page 4</i>
Report of the auditors	<i>page 5</i>
Financial statements:	
Income Statement	<i>page 6</i>
Balance sheet	<i>page 7</i>
Statement of changes in funds	<i>page 8</i>
Cash flow statement	<i>page 9</i>
Accounting policies	<i>pages 10 - 11</i>
Notes forming part of the financial statements	<i>pages 12 - 16</i>
Tables and graphs	
Sources of funding 1997 - 2001	<i>page 17</i>
Expenditure by country 1997 - 2001	<i>page 18</i>
Analysis of expenditure 2000 - 2001	<i>page 19</i>
Grant funds received 1997 - 2001	<i>page 20</i>
Analysis of grants received 2001	<i>page 21</i>
AMREF international offices	<i>page 22</i>



KEY:

-  MAIN PROGRAMME COUNTRIES
-  OCCASIONAL TRAINING INPUTS AND CONSULTANTANCIES



Board of Directors, Management and Administration

annual report and financial statements for the year ended 30 September 2001

Board of Directors

Mr. Bethuel Kiplagat (Chairman)
Mr. Bruce Bodner
Dr. Irwin Friedman
Mr. Francis Howard
Dr. Jessica Jitta
Dr. Adanetch Kidanemariam
Dr. Eunice Kiereini
Dr. Adeline Kimambo
Mr. Iain Knapman
Dr. Ulrich Laukamm-Josten
Mr. Hans Tuyt
Dr. Nizar Verjee
Dr. Alfonso Villalonga
Prof. Miriam Were

Acting Director General

Dr. Peter Ngatia

Management

- 1 Dr. Peter Ngatia, Director of Programmes
- 2 Mr. V. S. Thyagarajan: Director of Finance & Administration
- 3 Ms. Lynne Elliot: Director of International Training
- 4 Ms. Isabel Mbugua, Ag. Director of Information & Resource Mobilization
- 5 Dr. D. Bukenya: Tanzania Country Director
- 6 Ms. Mette Kjaer: Kenya Country Director
- 7 Ms. Blanche Pitt: South Africa Country Director
- 8 Dr. Vincent Oketcho: Uganda Country Director

Company Secretary

Mr. V. S. Thyagarajan (Acting)

Lawyers

Kaplan & Stratton

Bankers

Barclays Bank of Kenya Ltd
ABN AMRO – Nairobi (to 30th Nov 2001)
Citi Bank – Nairobi (since 1 Dec 2001)

The directors submit their report together with the audited financial statements for the year ended 30 September 2001, which disclose the state of affairs of the company.

Objectives of the foundation

The African Medical and Research Foundation mission is to empower disadvantaged people in Africa to enjoy better health. This mission is to be achieved by developing, testing and promoting the adoption of appropriate models for improving health; contributing to capacity development at all levels and contributing to the development of an enabling environment for health improvement.

Country of incorporation and registered office

The company is incorporated in Kenya as a company limited by guarantee under the Companies Act and is domiciled in Kenya.

The address of its registered office is:

Wilson Airport
P O Box 30125
Langata Road
NAIROBI.

Results

Recurrent expenditure of the Foundation amounted to US\$ 18.0 million in 2001 (US\$18.3 million in 2000).

Financial risk management and policies

The company's activities expose it to a variety of financial risks, including credit risk and the effects of changes in foreign currency exchange rates and interest rates. The company's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on its financial performance within the options available in Kenya to hedge against such risks.

Directors

The directors who held office between date of last report and the date of this report either throughout or in part were:

- | | |
|---|---|
| 1. Mr Bethuel Kiplagat | 10. Dr Ulrich Laukamm-Josten |
| 2. Mr Bruce Bodner | 11. Mr Hans Tuyt |
| 3. Mr Francis Howard | 12. Dr Nizar Verjee (appointed 4 Oct 2001) |
| 4. Dr Irwin Friedman | 13. Dr Alphonso Villalonga |
| 5. Dr Jessica Jitta | 14. Prof. Miriam Were (appointed 4 Oct 2001) |
| 6. Dr Adanetch Kidanemariam | 15. Mr Robert Bird (retired 2 Mar 2001) |
| 7. Dr Eunice Kiereini | 16. Dr John Nixon (retired 2 Mar 001) |
| 8. Dr Adeline Kimambo | 17. Dr Fred Binka (resigned 4 Oct 2001) |
| 9. Mr Iain Knapman (appointed 2 Mar 2001) | 18. Ms Isabella Ochola-Wilson (resigned 2 Mar 2001) |

The Director General Dr. John Batten resigned on 5 October 2001 and Dr. Erik Nordberg was appointed as the Ag. Director General on 29 Oct 2001. Tragically Dr. Nordberg passed away suddenly on 16 Jan 2002 due to a heart attack while on a project visit in Mozambique. Dr. Peter Ngatia has been asked to hold additional charge as Ag. Director General from 17 Jan 2002 until a new appointment is made.

Auditors

The company's auditors, PricewaterhouseCoopers, continue in office in accordance with Section 159(2) of the Companies Act.



By order of the Board

VS Thyagarajan, Company Secretary (Acting)

1 March 2002

The Companies Act requires the directors to prepare financial statements for each financial year that give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit. It also requires the directors to ensure that the company keeps proper accounting records that disclose, with reasonable accuracy, the financial position of the company. They are also responsible for safeguarding the assets of the company.

The directors accept responsibility for the annual financial statements, which have been prepared using appropriate accounting policies supported by reasonable and prudent judgements and estimates, in conformity with International Accounting Standards and the requirements of the Companies Act. The directors are of the opinion that the financial statements give a true and fair view of the state of the financial affairs of the company and of its surplus or deficit. The directors further accept responsibility for the maintenance of accounting records that may be relied upon in the preparation of financial statements, as well as adequate systems of internal financial control.

Nothing has come to the attention of the directors to indicate that the company will not remain a going concern for at least the twelve months from the date of this statement.



Bethuel Kiplagat, Chairman of the Board of Directors



Dr. Peter Ngatia, Ag. Director General

1 March 2002

We have audited the financial statements set out on pages 6 to 16. We have obtained all the information and explanations that to the best of our knowledge and belief were necessary for the purposes of our audit. The financial statements are in agreement with the books of account.

Respective responsibilities of directors and auditors


The directors are responsible for the preparation of financial statements, as set out on page 4. Our responsibility is to express an independent opinion on the financial statements based on our audit.

Basis of opinion

We conducted our audit in accordance with International Standards on Auditing. Those standards require that we plan and perform our audit to obtain reasonable assurance that the financial statements are free from material misstatement. An audit includes an examination, on a test basis, of evidence supporting the amounts and disclosures in the financial statements. It also includes an assessment of the accounting policies used and significant estimates made by the directors, as well as an evaluation of the overall presentation of the financial statements.

Opinion

In our opinion proper books of account have been kept and the financial statements give a true and fair view of the state of the company's financial affairs at 30 September 2001 and of its surplus and cash flows for the year then ended and comply with International Accounting Standards and the Kenyan Companies Act.




PricewaterhouseCoopers
Certified Public Accountants
Nairobi

1 March 2002

	Notes	2001 US\$'000	2000 US\$'000
Income			
Grants - restricted	1	12,888	13,938
Grants - unrestricted	1	2,784	2,295
Interest and gains on deposits	6a	143	179
Other income	2	2,220	2,410
Total income		18,035	18,822
Expenditure			
Direct programme activity		14,123	14,999
Programme monitoring and support	3a	1,337	1,039
Institutional development	3b	930	718
Administration	3c	1,601	1,568
Finance	6b	44	21
Total Expenses		18,035	18,345
Surplus/ (deficit) for the year		0	477

	Notes	2001 US\$'000	2000 US\$'000
Funds Employed			
Capital fund		4,796	4,194
General fund		529	286
Other funds	7	77	77
Total funds		<u>5,402</u>	<u>4,557</u>
Represented by			
Non-current assets			
Property, plant and equipment	9	4,796	4,194
Current assets			
Inventories	11	406	419
Debtors and prepayments	12	838	787
Grant income receivable		2,207	2,443
Cash and cash equivalents	13	4,551	3,449
		<u>8,002</u>	<u>7,098</u>
Current liabilities			
Payables and accrued expenses	14	2,084	2,116
Provision for liabilities and charges	8	129	282
Grants unexpended		5,183	4,337
		<u>7,396</u>	<u>6,735</u>
Net current assets		<u>606</u>	<u>363</u>
Total net assets		<u>5,402</u>	<u>4,557</u>

The financial statements on pages 6 to 16 were approved for issue by the board of directors on 1 March, 2002 and signed on its behalf by:



Bethuel Kiplagat, Chairman of the Board of Directors



Dr. Peter Ngatia, Ag. Director General

	General Fund US\$'000	Endowment Fund US\$'000	Other Funds US\$'000	Capital Fund US\$'000	Total Funds US\$'000
Year ended 30 September 2000					
At start of year:					
As previously reported	(366)	375	77	3,343	3,429
Prior year adjustment (see below)	-	(375)	-	-	(375)
	(366)	-	77	3,343	3,054
Surplus for the year	477	-	-	-	477
Transfers during the year	175	-	-	(175)	-
Additions during the year	-	-	-	1,026	1,026
	286	-	77	4,194	4,557
At end of year	286	-	77	4,194	4,557
Year ended 30 September 2001					
At start of year:					
As previously reported	286	375	77	4,194	4,932
Prior year adjustment (see below)	-	(375)	-	-	(375)
	286	-	77	4,194	4,557
Surplus for the year	-	-	-	-	-
Transfers during the year	299	-	-	(299)	-
(Deductions)/additions during the year	(56)	-	-	901	845
	529	-	77	4,796	5,402
At end of year	529	-	77	4,796	5,402

The prior year adjustment relates to investments held by African Medical Research Foundation Germany and removed from these financial statements as they are owned and controlled by African Medical Research Foundation Germany.

	Notes	2001 US\$'000	2000 US\$'000
Cash flows from operating activities			
Grants received	1	17,505	16,624
Other cash receipts	2	2,220	2,410
Cash paid to suppliers and employees		(17,924)	(17,857)
Interest paid		<u>(35)</u>	<u>(21)</u>
Net cash from operating activities		1,766	1,156
Cash flow from investing activities			
Payments to acquire fixed assets	9	(807)	(1,026)
Interest received		143	179
Net cash used in investing activities		<u>(664)</u>	<u>(847)</u>
Net increase in cash and cash equivalents		1,102	309
At start of year	13	3,449	3,140
At end of year	13	<u><u>4,551</u></u>	<u><u>3,449</u></u>

The principal accounting policies adopted in the preparation of these financial statements are set out below:

a Basis of preparation

The financial statements are prepared in accordance with and comply with International Accounting Standards. The financial statements are presented in US Dollars and prepared under the historical cost convention.

b Grant income

This represents donations received and receivable in respect of project expenditure incurred during the year:

- i) Expenditure incurred on projects for which a donation has not been received by the year-end and for which there are commitments from donors is carried forward as grant income receivable;
- ii) Grants and donations received in advance of the related expenditure are not taken as income but recorded as creditors (grants unexpended) at the year end and carried forward for utilization in the following year;
- iii) Air Ambulance recoveries are recognised in the year in which the service is provided;
- iv) The value of small gifts (e.g. medicines) and some personnel costs from local and overseas donors is not reflected in the financial statements.

c Foreign Currency

Transactions in currencies other than US dollars are converted to the measurement currency (US dollars) using the exchange rate of the mid of the month when the transactions took place. At the balance sheet date assets and liabilities held in other currencies are translated to US dollars using the exchange rates ruling at that date. Exchange gains or losses arising during the course of the year are taken up in the income and expenditure account.

d Property, plant and equipment

- i) Assets donated to the Foundation are included in the accounts at a valuation, which is an approximation of cost, as estimated by management. Property, plant and equipment purchased for donor-funded health programmes is expensed in the year of purchase. All other property, plant and equipment is initially recorded at cost.
- ii) Depreciation is calculated on the straight line basis to write down the cost of each asset, to its residual value over its estimated useful life as follows:

Buildings	5%
Aircraft	5% - 12.5%
Motor vehicles, medical, surgical and radio equipment	25%
Furniture, fittings and general equipment	12.5%

- iii) Gains and losses on disposal of property, plant and equipment are determined by reference to their carrying amount and are taken into account in determining operating profit.

e Inventories

Inventories are valued at the lower of cost and net realisable value. Cost is determined using the first-in,first-out method. Provision is made for obsolete and defective stocks.

f Receivables

Trade receivables are carried at amortised invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts at the year-end. Bad debts are written off in the year in which they are identified.

g Employee entitlements

The estimated monetary liability for employees' accrued annual leave entitlement at the balance sheet date is recognised as an expense accrual.

h Aircraft Maintenance

Provision is made to cover the estimated cost of the next major overhaul of aircraft on the basis of hours flown.

i Retirement benefit obligations

The company operates a defined contribution retirement benefit scheme for all its local employees. The scheme is administered by an insurance company and is funded from contributions from both the company and employees where applicable. In respect of employees on international contract, the company contributes to individual retirement benefit schemes chosen by the staff concerned.

The company's contributions of 14% of basic pay to the defined contribution scheme and the individual retirement benefit schemes are charged to the Income Statement in the year to which they relate.

j Capital Fund

The Capital Fund has been created to reflect the amounts donated for and monies spent on property, plant and equipment. The Fund is adjusted through the general fund to reflect movements in property, plant and equipment for acquisition, depreciation and disposals such that the capital fund is equivalent to the net book amount of the property, plant and equipment it represents.

k Comparatives

Where necessary, comparative figures have been adjusted to conform with changes in presentation in the current year.

1 Grant Funds

	Restricted Funds US\$'000	Unrestricted Funds US\$'000	2001 Total Funds US\$'000	2000 Total Funds US\$'000
Grants received	14,901	2,604	17,505	16,624
Opening balance b/fwd	800	1,094	1,894	2,576
	<u>15,701</u>	<u>3,698</u>	<u>19,399</u>	<u>19,200</u>
Closing balance c/fwd	(2,366)	(610)	(2,976)	(1,894)
Sub-total	<u>13,335</u>	<u>3,088</u>	<u>16,423</u>	<u>17,306</u>
Amount transferred to capital fund	(447)	(360)	(807)	(1,026)
Amount transferred to/(from) grant funds	-	56	56	(47)
Grants treated as income for the year	<u>12,888</u>	<u>2,784</u>	<u>15,672</u>	<u>16,233</u>

The closing balance of US\$ 2,976,000 is net of grants receivable of US\$ 2,207,000, which is net of provision for doubtful grants.

2 Other income

Income from Air Ambulance recoveries	1,684	1,771
Other income	536	639
	<u>2,220</u>	<u>2,410</u>

3 Expenditure

- a) Programme monitoring and support includes costs relating to Director of Programmes, Information Technology, Director General and at country level all overheads, except finance & administration and communication & information.
- b) Institutional Development includes costs relating to Director General, Director of Information & Resource Mobilization, Human Resources and at country level all costs relating to Communication & Information.
- c) Administration includes costs relating to corporate governance, Director General, Director of Finance and administration, internal audit and at country level all costs relating to finance & administration.

4 Operating surplus

	2001	2000
	US\$'000	US\$'000
The following items have been charged in arriving at surplus for the year:		
Depreciation on property, plant and equipment (Note 9)	293	175
Staff costs (Note 5)	7,229	6,890
Auditors' remuneration	14	14
Directors' remuneration		
- fees	-	-
- other	145	125
	<u> </u>	<u> </u>

5 Staff costs

The following items are included within staff costs:

Termination benefits	79	2
Retirement benefit costs - defined contribution plans	776	717
	<u> </u>	<u> </u>

The number of persons employed by the company at the year end were 528 (2000-554)

6 Finance costs/income

a) Income:

Interest and gains on deposits	143	179
	<u> </u>	<u> </u>

b) Costs:

Interest paid	44	21
	<u> </u>	<u> </u>

7 Other Funds

This is made up as follows:

HLM Fund	77	77
	<u> </u>	<u> </u>

The Health Learning Materials (HLM) Fund is a deposit of proceeds in Kenya Shillings from the sale of certain printing equipment, the income of which has been set aside for production of health learning materials.

8 Provisions for liabilities and charges

Aircraft Maintenance:

Opening balance at the start of year	282	203
Additional provision during the year	-	79
Provision utilised during the year	(153)	-
	<u> </u>	<u> </u>
At end of year	129	282
	<u> </u>	<u> </u>

9 Property, plant and equipment

	Land & buildings	Training centre construction in progress	Aircraft	Motor vehicles,	Furniture fittings & general equipment	Total
	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000	US\$'000
<u>Cost or valuation</u>						
At start of year	822	2,289	1,515	225	991	5,842
Additions	-	489	-	3	315	807
Disposals	-	-	-	(13)	(98)	(111)
Transfers	2,778	(2,778)	-	-	-	-
Reclassification	14	-	-	-	155	169
At end of year	<u>3,614</u>	<u>-</u>	<u>1,515</u>	<u>215</u>	<u>1,363</u>	<u>6,707</u>
<u>Depreciation</u>						
At start of year	267	-	419	209	753	1,648
Charge for the year	104	-	68	7	114	293
On disposals	-	-	-	(13)	(92)	(105)
Reclassification	14	-	-	-	61	75
At end of year	<u>385</u>	<u>-</u>	<u>487</u>	<u>203</u>	<u>836</u>	<u>1,911</u>
<u>Net book amount</u>						
At 30 September 2001	<u>3,229</u>	<u>-</u>	<u>1,028</u>	<u>12</u>	<u>527</u>	<u>4,796</u>
At 30 September 2000	<u>555</u>	<u>2,289</u>	<u>1,096</u>	<u>16</u>	<u>238</u>	<u>4,194</u>

In the opinion of the directors, there is no impairment of property, plant and equipment.

Property, plant and equipment which originally cost approximately US\$ 766,128 is fully depreciated but is still in use. If depreciation had been charged during the year on the cost of these assets the amount of property, plant and equipment and capital funds would have been reduced by about US\$ 124,752.

- 10** Apart from the investment with Merck Finck and Co, Germany since removed from these financial statements as a prior year adjustment, other investments shown as such in last year's financial statements have been reclassified and shown as short term deposits under note 13 below as these are accessible and not tied or locked up in long term securities, etc.

11 Inventories and work in progress	2001	2000
	US\$'000	US\$'000
Aviation spare parts and work in progress	269	259
Printing materials and work in progress	21	25
BDU books and manuals	50	69
Sundry stocks	66	66
	<u>406</u>	<u>419</u>
	<u><u>406</u></u>	<u><u>419</u></u>
 12 Receivables and prepayments		
Trade receivables	412	506
National Offices	39	28
Programme Advances	158	111
Staff debtors	36	53
Others	193	89
	<u>838</u>	<u>787</u>
	<u><u>838</u></u>	<u><u>787</u></u>
 13 Cash and cash equivalents		
Cash at bank and in hand	555	896
Short term deposits	3,996	2,553
	<u>4,551</u>	<u>3,449</u>
	<u><u>4,551</u></u>	<u><u>3,449</u></u>
 14 Payables and accrued expenses		
Trade payables	1,217	1,412
Accrued expenses	867	704
	<u>2,084</u>	<u>2,116</u>
	<u><u>2,084</u></u>	<u><u>2,116</u></u>

15 Bank Overdraft

The Foundation has an overdraft facility of KShs 30 million (US\$400,000). The facility is secured by a floating debenture over the Foundation's fixed and moveable property.

16 Taxation

No tax is provided for in these financial statements, as the Foundation is exempt from Kenyan taxation.

17 Contingent liabilities

In the ordinary course of business the company has given guarantees amounting to US\$ 81,000 (2000: US\$ 81,000) to third parties.

18 Capital Commitments


Capital expenditure contracted for at the balance sheet date but not recognised in the financial statements is as follows:

	2001	2000
	US\$'000	US\$'000
Property, plant and equipment	35	589


19 Trust Funds

- a) A Trust Fund was constituted under a Trust Deed dated 6 November 1995 with its registered office in London. It has six Trustees of whom AMREF can nominate one. The principal activity of the trust is to raise funds to be held in an endowment fund to generate income to provide support for the work of AMREF for restricted lists of purposes that fall within the criteria outlined in the Trust Deed. Income from the Trust Fund is recognized in the Income Statement in the period in which it is received.

- b) An Endowment Fund was established by AMREF Germany with funds raised from donors in Germany with the aim of providing investment income to help defray a proportion of institutional costs of AMREF HQ and Country Programmes. Income from the Endowment Fund is recognised in the Income Statement in the period in which it is received.



	1996/97	1997/98	1998/99	1999/00	2000/01
Public grants	6.9	7.6	8.3	10.1	10.7
Private donations	4.2	5.0	6.1	6.7	5.7
Other funds	2.3	2.1	2.1	2.6	2.4
Total funds	13.4	14.7	16.5	19.4	18.8



	1996/97	1997/98	1998/99	1999/00	2000/01
Kenya	4.0	4.9	5.7	7.5	6.9
Regional	2.1	1.9	2.0	2.3	2.7
Uganda	1.7	2.4	2.1	3.0	2.6
Tanzania	2.5	2.3	2.3	2.1	2.0
Mozambique	0.0	0.0	0.2	0.5	0.6
Ethiopia	0.0	0.1	0.1	0.2	0.4
S.Africa	0.2	0.3	0.4	0.3	0.4
Somalia	0.5	0.5	0.5	0.5	0.3
Rwanda	0.7	0.2	0.1	0.1	0.1
Headquarters	1.6	1.7	2.0	1.9	2.0
Capital	0.1	0.4	1.1	1.0	0.8
Total Expenditure	13.4	14.7	16.5	19.4	18.8

Priority Intervention Areas

	2001	2000
	US\$'000	US\$'000
Family health	3,640	4,927
Training	2,747	2,292
Emergency services	1,781	1,734
Safe water supply & basic sanitation	1,399	1,088
Disaster preparedness & response	987	1,915
Clinical outreach	897	869
Malaria	808	739
Health Learning Materials	119	181
	<hr/>	<hr/>
	14,123	14,999

HQ & Country Offices

Staff costs	2,588	1,872
Travel & Transport	504	343
Office Costs	548	744
Communications	36	53
Finance	44	209
	<hr/>	<hr/>
	3,912	3,346
Total operating Expenditure	18,035	18,345
Capital Expenditure	807	1,026
	<hr/>	<hr/>
	<u>18,842</u>	<u>19,371</u>

	1996/97		1997/98		1998/99		1999/2000		2000/01	
	US\$ 000	Percent %								
UK	1,486	13.4%	1,996	13.7%	2,411	18.9%	2,789	16.8%	3,211	18.3%
USA	1,841	16.6%	2,805	19.2%	1,751	13.8%	3,569	21.5%	3,039	17.4%
Canada	1,976	17.8%	1,446	9.9%	1,074	8.4%	1,455	8.8%	1,988	11.4%
Ireland	658	5.9%	830	5.7%	565	4.4%	1,058	6.4%	1,638	9.4%
Netherlands	1,004	9.1%	589	4.0%	1,140	9.0%	1,002	6.0%	1,302	7.4%
Italy	246	2.2%	408	2.8%	476	3.7%	703	4.2%	971	5.5%
Germany	1,154	10.4%	1,361	9.3%	1,480	11.6%	795	4.8%	938	5.4%
Spain			456	3.1%	563	4.4%	707	4.3%	894	5.1%
International organisations	489	4.4%	530	3.6%	250	2.0%	555	3.3%	611	3.5%
Sweden	244	2.2%	2,018	13.8%	1,005	7.9%	1,426	8.6%	555	3.2%
Kenya	519	4.7%	609	4.2%	895	7.0%	519	3.1%	486	2.8%
Tanzania	381	3.4%	563	3.9%	469	3.7%	593	3.6%	403	2.3%
Norway	436	3.9%	460	3.1%	7	0.1%	278	1.7%	394	2.3%
Austria	14	0.1%	20	0.1%	192	1.5%	247	1.5%	366	2.1%
Denmark	204	1.8%	158	1.1%	211	1.7%	338	2.0%	278	1.6%
Uganda					14	0.1%	172	1.0%	140	0.8%
Switzerland	215	1.9%	141	1.0%	200	1.6%	199	1.2%	61	0.3%
South Africa	14	0.1%	129	0.9%	16	0.1%	91	0.5%	50	0.3%
Other countries	207	1.9%	90	0.6%	8	0.1%	128	0.8%	180	1.0%
Totals	11,088	100.0%	14,609	100.0%	12,727	100.0%	16,624	100.0%	17,505	100.0%

	Government and official agencies US\$ 000	Foundations NGOs and general public US\$ 000	Total grant income US\$ 000	2000/01 percent	1999/00 percent
UK	1,517	1,694	3,211	18.3%	16.8%
USA	1,869	1,170	3,039	17.4%	21.5%
Canada	1,957	31	1,988	11.4%	8.8%
Ireland	1,638	-	1,638	9.4%	6.4%
Netherlands	223	1,079	1,302	7.4%	6.0%
Italy	-	971	971	5.5%	4.2%
Germany	561	377	938	5.4%	4.8%
Spain	894	-	894	5.1%	4.3%
International Organisations	611	-	611	3.5%	3.3%
Sweden	549	6	555	3.2%	8.6%
Kenya	218	268	486	2.8%	3.1%
Tanzania	169	234	403	2.3%	3.6%
Norway	392	2	394	2.3%	1.7%
Austria	281	85	366	2.1%	1.5%
Denmark	278	-	278	1.6%	2.0%
Uganda	97	43	140	0.8%	1.0%
Switzerland	16	45	61	0.3%	1.2%
South Africa	-	50	50	0.3%	0.5%
Other countries	50	130	180	1.0%	0.8%
Totals	<u>11,320</u>	<u>6,185</u>	<u>17,505</u>	<u>100.0%</u>	<u>100.0%</u>
2000/2001 percentage	64.7%	35.3%	100.0%		
1999/2000 percentage	60.0%	40.0%	100.0%		

AFRICAN MEDICAL AND RESEARCH FOUNDATION (A Company Limited by Guarantee) (Incorporated in Kenya)

FOUNDERS: Sir Archibald McIndoe †, Dr Thomas D. Rees, Sir Michael Wood †

PATRONS: H.E. President Daniel T. arap Moi, CGH,MP; HRH Prince Bernard of The Netherlands.

HEADQUARTERS: African Medical & Research Foundation, P.O. Box 00506 - 27691 Nairobi • Telephone:(+254 2) 605220
Email:fundraising@amrefhq.org • Telex:23254 AMREF • Faxes:(+254 2) 609518 (main),606345 (Fundraising/Communication)

Acting Director General: Peter Ngatia • **International board chairman** - Bethuel Kiplagat

Africa

ETHIOPIA

AMREF-Ethiopia, 227B Asmara Road, Worreda 18, Kabele 07, P.O. Box 20855, Addis Ababa
Tel: +251 1 531919 Ext 271 • Fax: +251 1 534148
Email:rhein.amref@mail.telecom.net.et
Country Representative: Roma Hein

KENYA

AMREF-Kenya, P.O. Box 30125, Nairobi
Tel: (+254 2) 604651-9, 500508
Email:info@amrefke.org • Faxes:606340 (Administration), 336886 (Clinical), 502984 (Aviation) • Country Director: Mette Kjaer

MOZAMBIQUE

AMREF - Mozambique, Av. Angostinho Neto, 1584, P.O. Box 433, Maputo • Tel: 258 1 424913
Fax: 258 1 310 810 • E-mail:amrefmoz@sortmoz.com • Country Representative: Thelma Leifert

SOUTH AFRICA

AMREF-South Africa, P.O. Box 329 Pretorius Street, Momentum Centre, Pretoria 001
Tel: (+012) 320-1332/3; Fax: (+012) 320-1335
E-mail:amrefsa@iafrica.com
Country Director: Blanche Pitt

TANZANIA

AMREF-Tanzania, Ali Hassan Mwinyi Road, P.O. Box 2773, Dar es Salaam • Tel: +007 51-116610
Fax: +007 51- 115823 • E-mail:info@amreftz.org
Country Director: Daraus Bukenya

UGANDA

AMREF-Uganda, P.O. Box 10663 Kampala, Tel: (256-41) 250319/344579 • Fax:(256-41) 344565 • E-mail: info@amrefug.org
Country Director: Vincent Oketcho

Europe and North America

AUSTRIA

AMREF-Austria, Gesellschaft fuer Medizin und Forschung in Afrika e.V., inc. Flying Doctors Service, Waagplatz 3, A5020 Salzburg
Tel: +43 (0)662 840101 • Fax: +43(0)662 847820
Email:amrefat@salzburg.co.at
Chairman: Walter Schmidjell

CANADA

AMREF-Canada, 489 College Street, Suite 407 Toronto, Ontario M6G 1A5 • Tel: +1 (416) 961-6981 Fax: +1 (416) 961-6984
E-mail:amref.canada@amref.org
Acting Director: Regan Mancini
Chairman: Alan Torrie

DENMARK

Den Afrikanske Laegefond, Gorrissen Federspiel Kierkegaard, 12 H.C. Andersens Boulevard, DK- 1553, Copenhagen V
Tel: +45 33 41 41 41 • Fax: +453341 41 28
E-mail:tf@gfklaw.dk
Chairman: Thomas Federspiel

FRANCE

Association pour la Medecine et la Recherche en Afrique. 38 rue des Sablons 75116 Paris
Tel/Fax: +33 1 40 87 13 87 • E-mail:tzarina@club-internet.fr • Directeur: Zarina de Bagneux
Chairman: Francois Gautheron

GERMANY

AMREF, Gesellschaft fur Medizin und Forschung in Afrika e.V. Flying Doctor Services, Mauerkircher Str. 155, D-81925 Munchen • Tel: +49 89 9811 29 • Fax: +4989 98 11 89 • E-mail:info@AMREFgermany.de
Chairman: Leonore Semler.

ITALY

AMREF-Italia, Fondazione Africana per la Medicina e la Ricerca, Via Luigi Settembrini 30, 00195, Roma • Tel: +39 06 320 22 22
Fax: +39 06 320 22 27 • E-mail: info@amref.it
Director: Thomas Simmons • Milan Office: Amref Eventi, Via Domenico Cirillo, 14, 20154 Milano • Tel/Fax: 39 02 345 1940
E-mail:milano@amref.it
Chairman: Mrs Ilaria Borletti

MONACO

AMREF-MONACO, Galerie Princess Stephanie 8, Avenue des Papalins 98000 Monaco
Tel/Fax: (00377) 97770808
E-mail:amrefmonaco@monaco377.com
Chairman: Anne Wattebled

THE NETHERLANDS

Stichting AMREF-Nederland, Stevensbloem 269, 2331 JD Leiden • Tel: +31 71 576 94 76
Fax: +31 71 5763777 • E-mail:amrefadm@bart.nl • Executive Director: Constance van Haeften • Chairman: J.J Tuyt

SPAIN

Fundacion AMREF-Espana, Av. Pio XII 57, Portal D Bajo Izquierda 28016 • Madrid Tel: 34-913430211 & 3491 635007 • Fax: +3491 345 0413 • E-mail: amref@fundacionamref.org
Director: Rafael Ruiz Llach
Chairman: Dr Alfonso Villalonga Navarro

SWEDEN

African Medical and Research Foundation, AMREF- Sweden, S-115 21 Stockholm, Sweden
E-mail:amref@telia.com
Chairman: Helena Bonnier

UNITED KINGDOM

AMREF-UK, 4 Grosvenor Place London SW1 X 7Hj • Tel: +44 (020) 7201 6070 • Fax: +44 (020) 7201 6170 • E-mail: amref.uk@amref.org
Director: Alexander Heroys
Chairman: Alistair Boyd, CMG

UNITED STATES OF AMERICA

AMREF-USA, Inc., 19 West 44th Street, Room 710, New York, NY 10036 • Tel: +1 212 768 2440. Cables: AMREF USA NY • Fax: +1 212 7684230 • E-mail: amrefusa@amrefusa.org
Director: Priscilla S. Goldfarb.
Chairman: Charles H.F. Garner

WEBSITE:www.amref.org
† Deceased



AMREF

African Medical and Research Foundation

HEADQUARTERS: P.O. Box 00506 - 27691 Nairobi, Kenya

Tel: (+254 2) 605220 • **Faxes:** (+254 2) 609518 (main), 606345 (Fundraising/Communication)

Email: fundraising@amrefhq.org • **Website:** www.amref.org • **Telex:** 23254 AMREF